Kaneka launches brain aneurysm coil in Europe after securing EU certification

Kaneka Corp. announced it has begun sales of its i-ED COIL, a brain aneurysm embolization coil, in Europe following the product’s receipt of EC certification under the European Union’s Medical Device Regulation in July. The device will be distributed primarily across Europe through Kaneka Medical Europe N.V.

The i-ED COIL, already in use in Japan since 2019, is designed to offer exceptional flexibility through its specialized wire thickness and unique structural features. This design allows physicians to pack coils more densely within aneurysms, including those with irregular shapes, which can help reduce the risk of rupture.

“The i-ED COIL provides world-class flexibility, enabling treatment of a wider variety of aneurysms while supporting improved patient outcomes,” the company said in a statement. “Its role in reducing rupture risk has been highly regarded by physicians.”

Kaneka’s Health Care Solutions Unit develops and markets devices for cardiac, peripheral vascular, cerebrovascular, and gastrointestinal disease treatments. The company said it aims to expand the global reach of products like the i-ED COIL and achieve 300 billion yen in sales by 2030.

Rooted in its corporate philosophy, “Wellness First,” Kaneka said it remains committed to advancing medical care accessibility worldwide through science and innovation.

Advances in aneurysm treatment and neurovascular devices

The launch of Kaneka’s i-ED COIL comes as innovation in the neurovascular device market accelerates, driven by growing demand for minimally invasive treatments of brain aneurysms and other cerebrovascular conditions.

In recent years, device makers have focused on improving coil flexibility, deliverability, and packing density—key factors in safely filling aneurysms and reducing the chance of recurrence. Advances in material science, including the use of hybrid polymers and shape-memory alloys, have made it possible to design coils that conform more precisely to an aneurysm’s anatomy while maintaining stability during placement.

Another major area of progress involves adjunctive devices such as flow diverters and stent-assisted coiling systems, which help manage complex aneurysms that previously required open surgery. These technologies redirect blood flow away from the aneurysm sac, promoting natural healing of the vessel wall.

Digital tools are also reshaping the field. Three-dimensional imaging and artificial intelligence-driven planning software are allowing neurointerventionalists to simulate procedures and select optimal coil configurations before treatment. These innovations have been associated with shorter procedure times, reduced radiation exposure, and improved patient outcomes.

As the population ages and diagnostic imaging becomes more widespread, early detection of unruptured aneurysms is increasing. This trend, coupled with the continued evolution of minimally invasive technology, is expected to sustain strong growth in the global neurointerventional device market for years to come.